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Abstract
Twenty-ﬁve patients with proven or probable invasive fungal infections (IFIs) who experienced two or more episodes of voriconazole
therapeutic drug monitoring (TDM) at a tertiary referral hospital were reviewed to explore the association between serum trough con-
centrations and outcomes of IFI. Microbiological and/or clinical success, in addition to IFI-related mortality, was assessed. We performed
two separate analyses, one based on the initial trough voriconazole concentration at steady state, and the other on the median trough
voriconazole concentration (derived from repeated TDM episodes) for each patient. Large interpatient and intrapatient variability of
trough plasma voriconazole concentrations was observed, with no correlation between dose and concentration (r = 0.065). Classiﬁca-
tion and regression tree analysis revealed an association between IFI-related mortality and initial trough voriconazole concentrations,
with patients more likely to die when their initial steady-state concentration was £0.35 mg/L (p 0.004; OR 11, 95% CI 2.9–41.2). Suc-
cessful outcomes were more likely among patients with a median trough voriconazole concentration >2.2 mg/L (p 0.003; OR 2.7,
95% CI 1.4–5). Nineteen adverse events, with four severe events, were documented in 14 patients. Patients with severe adverse events
had higher median voriconazole concentrations than the remaining cohort (2.38 mg/L vs. 1.30 mg/L; p <0.04). All adverse events
resolved after cessation of voriconazole treatment. Our data suggest that voriconazole TDM is appropriate for all patients as soon as
steady state is achieved. For non-responding patients with low trough concentrations, the association with IFI-related mortality indicates
the need for dose adjustments to achieve and sustain voriconazole concentrations.
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Introduction
Voriconazole is a triazole with broad-spectrum antifungal
activity, currently considered to be the ﬁrst-line agent for the
treatment of invasive aspergillosis [1,2]. Pharmacodynamic
studies of voriconazole suggest a concentration–response
relationship [3,4]. Several pharmacokinetic variables inﬂuence
the steady-state voriconazole plasma concentration. These
include oral bioavailability, which is inﬂuenced by meals [5];
non-linear dose–response curves with disproportional altera-
tions in serum concentrations following dose modiﬁcations in
adults; high interpatient and intrapatient variability; and hepatic
metabolism, which is altered by numerous medications [6,7].
Therefore, it has been suggested that therapeutic drug moni-
toring (TDM) of voriconazole concentrations should be per-
formed to maximize efﬁcacy and to minimize adverse events
[7–9]. An association between poor outcome and voriconazole
concentrations, varying from 0.25 to 2 mg/L, has been observed
[8,10–12]. Limited and conﬂicting data exist concerning an asso-
ciation between voriconazole concentrations and treatment
success, i.e. microbiological and/or clinical cure [8,10–12]. To
address this issue, we reviewed the medical records of all
patients who experienced voriconazole TDM at St Vincent’s
Hospital, Sydney, to examine the association between plasma
trough voriconazole concentrations and mortality, clinical and
microbiological success, and adverse events during treatment.
Patients and Methods
All adults for whom two or more voriconazole concentra-
tions were determined from July 2004 to April 2007 were
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identiﬁed from the Clinical Pharmacology database at St Vin-
cent’s Hospital, a tertiary-referral hospital with solid organ
and bone marrow transplant units. Data were collected from
medical records and pathology request forms. The parame-
ters obtained included the following: patient age, gender, and
weight; underlying disease; immunosuppression (corticoster-
oids and/or alternative immunosuppressive agents at the time
of TDM); comorbidities; voriconazole indication, dose, and
mode and duration of administration; timing of dose in rela-
tion to TDM; changes in voriconazole dosing; adverse events;
use of alternative antifungals; number and type of potentially
interacting medications; and outcome.
Invasive fungal infections (IFIs) were classiﬁed in accor-
dance with previously deﬁned criteria [13]. All patients were
followed for a minimum of 3 months after the completion of
voriconazole therapy. Fungus-related mortality was deﬁned
as mortality among patients with ante-mortem or post-mor-
tem evidence of IFI. Patients were considered as dying
because of IFI or with IFI in the absence or presence of
other contributing factors, respectively. A successful out-
come was deﬁned as clinical improvement and/or evidence
of microbiological cure; otherwise, patients were classiﬁed as
failing antifungal therapy. A recorded adverse event, based,
where appropriate, on previously deﬁned laboratory values
[14], was attributed to voriconazole in the absence of any
other explanation (i.e. other medications with similar side
effects) [15]. All other adverse events were deemed to be
probably related to voriconazole.
Quantitation of voriconazole in plasma
Voriconazole was quantitated in human plasma using an in-
house-validated HPLC assay with UV detection. Brieﬂy,
plasma (0.5 mL) was extracted with 1-chlorobutane (6.0 mL)
after addition of the internal standard (L-754394; an analogue
of ritonavir). The organic solvent was evaporated to dryness,
and the residue was resuspended in 350 lL of mobile phase.
Separation was performed on a Luna Phenyl Hexyl column
(Phenomenex) with a mobile phase of acetonitrile and
10 mM phosphate buffer (pH 7.0; 50 : 50 v/v). Detection of
voriconazole and internal standard was performed at
255 nm, at a ﬂow rate of 2.0 mL/min and a column tempera-
ture of 40C. The calibration range was 0.1–5.0 mg/L, with
accuracy <5% relative standard deviation and precision <5%
coefﬁcient of variation.
Statistical analysis
Classiﬁcation and regression tree (CART; Salford Systems,
San Diego, CA, USA) analysis was used to identify the vori-
conazole concentrations associated with mortality and
treatment success. Stringent criteria (pruning and ten-fold
cross-validation) were used in the CART analysis to select
the optimal nested subtree with the smallest misclassiﬁcation
cost. The remaining statistical analysis was conducted using
the SPSS software v.11.0 for Windows. Appropriate tests for
continuous and categorical variables and for survival were
used after determination of data distribution.
For plasma voriconazole concentrations to be included in
any of the analyses, levels were required to be taken at
steady state and obtained 12 h after the last dose (on evi-
dence from both the request forms and medication charts
for each patient). Voriconazole was considered to be at
steady state after 3 days of administration following a loading
dose or after 5 days without a loading dose [10]. Ethics
approval was obtained (SVH HREC Approval No. Q06/158).
Results
Forty-six eligible patients were identiﬁed. Twenty-one were
excluded for the following reasons: inability to conﬁrm that
at least one measurement corresponded to a voriconazole
trough concentration at steady state (n = 7); incomplete
medical data (n = 3); or voriconazole treatment for possible
fungal infection or prophylaxis (n = 11). The characteristics
of the remaining 25 patients, all of whom received voriconaz-
ole for treatment of proven or probable fungal infection, are
presented in Table 1. Sixteen (64%) patients were alive
3 months after cessation of voriconazole treatment. Nine
patients died, and a post-mortem was performed on 44% (4/9)
of them. Characteristics of the ﬁve (56%) patients whose
deaths were related to IFI are summarized in Table 2. It is of
note that a single patient had persistently low voriconazole
concentrations despite several dose modiﬁcations, with no
potential drug interaction being identiﬁed to account for these
persistently low levels.
The remaining four deaths occurred for non-IFI related
reasons, i.e. disease recurrence, Pseudomonas bacteraemia,
refractory disease (acute myeloid leukaemia), and autopsy-
proven graft-versus-host disease. In two of these four
patients, treatment was considered to have failed, because of
ongoing microbiological evidence of fungal infection in the
respiratory tract due to Scedosporium proliﬁcans and Aspergil-
lus fumigatus. Treatment failure thus occurred in a total of
ten patients, with a median time to failure of 35 treatment
days (range 7–85 days).
A total of 147 trough voriconazole concentrations were
determined for 25 patients (median of three TDM episodes
per patient; range 2–26), which corresponds to 2733 treat-
ment-days (median duration of treatment 80 days, range 11–
730 days) and an average voriconazole dose of 6.7 mg/kg per
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day (Table 3). Voriconazole concentrations were measured
at a median of 7 days (25–75% interquartile range 4–10 days)
after starting treatment or dose adjustment. TDM was
performed at the discretion of the treating physicians,
throughout the study period, owing to concerns about fail-
ure (48%), a suspected adverse event (24%), and/or interac-
tions with other medications (16%). As clinicians were not
given a predeﬁned therapeutic range, dose adjustments were
similarly left to the treating doctor, and usually occurred
when poor clinical responses were associated with low vo-
riconazole concentrations or when adverse events were
deemed to be associated with high levels.
The results related to the 147 TDM episodes are summa-
rized in Fig. 1. The median trough voriconazole concentra-
tion was 0.9 mg/L (mean 1.73 mg/L; range 0–20 mg/L), with
TABLE 1. Characteristics of 25 patients who experienced
therapeutic drug monitoring of voriconazole during treat-
ment of invasive fungal infections
Characteristic Number (%)
Male sex 12 (48)
Median age: 47 years (range: 24–77 years)
Underlying disease
None 1 (4)
HSCT or prolonged neutropenia 5 (20)
SOT 12 (48)
HIV 2 (8)
Chronic steroid use 5 (20)
Comorbidities
None 9 (36)
Multiple 5 (20)
Diabetes 10 (40)
Chronic cardiac failure 6 (24)
Chronic renal failure 5 (20)
Immunosuppression 14 (56)
Neutropenia 4 (16)
Infection
Proven 15 (60)
Probable 10 (40)
Infection site
Lungs 17 (68)
Othera 8 (32)
Organism isolated
Yeast (5)
Candida non-albicans 3 (12)
Cryptococcus sp. 2 (8)
Moulds (20)
Aspergillus sp. 15 (60)
Scedosporium apiospermum 4 (16)
Unidentiﬁed 1 (4)
Outcomes
Survival 16 (64)
Treatment success 13
Treatment failure 3
Death 9 (36)
Treatment success 2
Treatment failure 7
Reasons for mortality
Due to IFI 4
With IFI 1
Otherb 4
HIV, human immunodeﬁciency virus; IFI, invasive fungal infection; HSCT, haemo-
poietic stem cell transplantation; SOT, solid organ transplantation.
aSinusitis (two patients), central nervous system infection (two), osteomyelitis
(two), fungaemia (one), and generalized infection (one).
bProgressive underlying disease (two patients), graft-versus-host disease (one),
and bacteraemia (one).
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32% of total measurements (n = 47) <0.5 mg/L and 5.4%
(n = 8) undetectable (<0.1 mg/L). A concentration >2 mg/L
was detected in 30.6% of total cases (n = 45), and concen-
trations >3 mg/L (range 3.1–20 mg/L) occurred in 17% of
measurements (n = 25). Substantial variabilty of voriconazole
concentrations among patients (interpatient) and within the
same patient (intrapatient) was evident with both oral and
intravenous dosing (Fig. 2). There was no correlation
between dose and concentration (r = 0.065).
Nineteen adverse events were documented in 56%
(n = 14) of patients (Table 4). Four events were deﬁnitely
attributed to voriconazole, i.e. visual disturbances (n = 2),
rash (n = 1), and hallucinations (n = 1). Fifteen adverse
events were probably related to voriconazole, with four
cases of creatinine increase and 11 liver function test abnor-
malities. Patients with severe adverse events (grade 4 trans-
aminitis (n = 2), rash, and hallucinations) had signiﬁcantly
higher concentrations (median 2.38 mg/L) than the rest of
the cohort (median 1.30 mg/L, p <0.04). No linear correla-
tion was found between concentrations and adverse events
as manifested in laboratory ﬁndings (liver function tests,
creatinine levels). All severe adverse events resolved after
cessation of voriconazole.
Using CART analysis, it was determined that the best pre-
dictor for associated IFI-related mortality was the initial
steady-state trough voriconazole concentration, with all
patients (n = 3) dying when the initial concentration was
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FIG. 1. Results of 147 serum voriconazole therapeutic drug moni-
toring (TDM) measurements performed for 25 patients treated for
invasive fungal infections. TDM results are stratiﬁed by weight-
adjusted daily voriconazole dose. Two serum trough voriconazole
concentrations are not shown. Both of these concentrations (13.1
and 20 mg/L) occurred in the same patient prescribed a daily
weight-adjusted dose of 9 mg/kg.
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FIG. 2. Interpatient and intrapatient serum trough voriconazole con-
centration variability at different weight-adjusted daily doses. Each
box plot represents serum trough voriconazole concentrations
(median, minimum, maximum, and interquartile range) of a single
patient who had two or more therapeutic drug monitoring (TDM)
measurements at a speciﬁc weight-adjusted daily dose. (Some
patients may be represented more than once, if they had two or
more TDM measurements at different doses and/or via different
administration routes.) Solid and dashed box plots refer to oral and
intravenous voriconazole administration respectively. The interquar-
tile range is given only for patients with four or more TDM mea-
surements at a speciﬁc dose.
TABLE 3. Details of voriconazole therapeutic drug monitor-
ing for the 25 patients treated for invasive fungal infection
Reason for TDM (no. of patients (%))
Efﬁcacy 12 (48)
Toxicity 6 (24)
Interacting drugs 4 (16)
Undetermined 3 (12)
Voriconazole administration (no. of patients (%))
Intravenous initially or entirely 6 (24)
Oral entirely 19 (76)
Average daily dose mg/kg (range) 6.7 (2.1–11.4)
Median days of treatment duration (range) 80 (11–730)
Median number of days before initial TDM (IQR) 9 (4–10)
Median number of treatment days before failure (range) 35 (7–85)
IQR, interquartile range; TDM, therapeutic drug monitoring.
TABLE 4. Adverse events among 25 patients who had TDM
of voriconazole during treatment of IFIs
Adverse eventsa
Number
of
patientsb
Deﬁnitely
associated with
voriconazolea
Severe
adverse
eventa
Any 14 4 4
LFT impairment 11 0 2
Visual disturbances 2 2 0
Hallucinations 1 1 1
Photosensitive rash 1 1 1
Renal impairment 4 0 0
LFT, liver function test.
aSee text for details and deﬁnitions. All events were reversible following cessa-
tion of voriconazole.
bFive patients had more than one adverse event.
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£0.35 mg/L, as compared with only 9% of patients (two of
22) when the initial concentration was above 0.35 mg/L. This
corresponds to an 11-fold increased risk of death among
patients with an initial trough concentration £0.35 mg/L
(OR 11, 95% CI 2.9–41.2; p 0.004; Table 5).
Initial voriconazole concentrations obtained within 7 days
(n = 13) and 10 days (n = 19) of treatment were also analy-
zed separately. The association between outcomes and con-
centrations £0.35 mg/L remained for concentrations
obtained within 10 days (p 0.01) but not for concentrations
obtained within 7 days (p 0.077).
Although deceased patients were likely to be older than
the patients who survived (median age 56 years vs.
43.5 years), have comorbidities (4/5 vs. 14/22), have proven
(as opposed to probable) fungal infections (5/5 vs. 10/20),
and have mould (as opposed to yeast) infections (5/5 vs. 15/
20), immunosuppression was the only other host factor sig-
niﬁcantly associated with IFI-related mortality (5/5 vs. 9/20;
p 0.046).
According to multivariate analysis, including initial trough
voriconazole concentration and immunosuppression, concen-
tration £0.35 mg/L remained associated with IFI-related mor-
tality (p 0.034; adjusted OR 18, 95% CI 1.2–260.9).
A median voriconazole concentration >2.2 mg/L was
determined, using CART analysis, to be the best predictor of
microbiological or clinical success. All nine patients with
median trough voriconazole concentrations >2.2 mg/L had
favourable outcomes, as compared with only 37.5% of
patients (six of 16) with a median concentration £2.2 mg/L
(OR 2.7; 95% CI 1.4–5; p 0.003, Table 5).
Although CART analysis did not reveal the initial or the
median trough voriconazole concentrations as the principal
variables in treatment success or IFI-related mortality,
respectively, both these variables were statistically signiﬁcant.
An initial trough voriconazole concentration >0.35 mg/L was
associated with a three-fold increase in treatment success
(OR 3.1; 95% CI 1.7–5.8, p 0.052), whereas a median trough
concentration <2.2 mg/L was associated with IFI-related
mortality (OR 1.5; 95% CI 1.1–2; p <0.01) (Table 5). None
of these associations changed when all patients who died
due to non-fungal causes were considered as antifungal treat-
ment failures.
Discussion
Our data suggest that, for optimal outcomes, adequate initial
steady-state voriconazole concentrations (>0.35 mg/L) are
required. In addition, these concentrations should be sustained
throughout the treatment course, with a median trough con-
centration of >2.2 mg/L. Adverse events tended to occur in
patients with higher voriconazole concentrations and resolved
once the drug was discontinued. However, no concentration
was identiﬁed that was invariably associated with an adverse
event. All of these associations were observed despite large in-
terpatient and intrapatient concentration variability with both
oral and intravenous dosage regimens.
To our knowledge, this is the ﬁrst report of an apparent
association between voriconazole concentration and survival.
This adds to the weight of data supporting the usefulness of
voriconazole TDM for optimizing treatment beneﬁt. Two
questions remain unanswered: (i) is there a therapeutic range
of voriconazole, and/or an optimal target concentration; and
(ii) what is the most appropriate strategy for voriconazole
TDM in clinical practice?
No target concentration of voriconazole has been estab-
lished for treatment success. Although one retrospective
study documented a favourable response (CART analysis),
this was based on random concentrations rather than trough
concentrations [11]. The applicability of random concentra-
tions in clinical practice is uncertain.
An FDA analysis of data from 280 patients and an open-
label, multicentre trial concerning invasive aspergillosis
suggested a trend towards better outcomes in patients with
mean concentrations >0.5 mg/L and failure with concentra-
tions <0.5 mg/L, respectively [8,10].
In a recently published study [12], a trough concentration
£1 mg/L was chosen on the basis of in vitro susceptibility
breakpoints, despite these being validated for yeast infections
only [6,16]. Using this cut-off, poor clinical and/or radiologi-
TABLE 5. Associations of voriconazole concentration with
mortality and documented treatment success among 25
patients treated for invasive fungal infection
Mortality due
to or with
invasive fungal
infection
Microbiological
and/or clinical
success
Voriconazole concentration Death Survival Failure Success
Initial trough concentrationa
<0.35 mg/L 3 0 3 0
>0.35 mg/L 2 20 7 15
OR and 95% CI 11 (2.9–41.2)b 3.1 (1.7–5.8)b
Median trough concentrationa
<2.2 mg/L 5 11 10 6
>2.2 mg/L 0 9 0 9
OR and 95% CI 1.5 (1.1–2.0)c 2.7 (1.4–5.0)c
aInitial and median concentration cut-offs were determined by classiﬁcation and
regression tree analysis.
bAn initial concentration <0.35 mg/L was signiﬁcantly associated with IFI-related
mortality and microbiological and/or clinical success.
cA median concentration >2.2 mg/L was signiﬁcantly associated with IFI-related
mortality and microbiological and/or clinical success.
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cal responses were associated with low concentrations.
Importantly, good clinical outcomes followed dose modiﬁca-
tions resulting in concentrations >1 mg/L in all six patients
[12]. However, this level does not ensure success, as ﬁve
IFI-related deaths occurred among patients with concentra-
tions >1 mg/L. In addition, breakthrough yeast infections
have been reported at concentrations up to 2 mg/L in
patients receiving voriconazole prophylaxis [17]. In our
study, IFI-related mortality was associated with a concentra-
tion lower (<0.35 mg/L) than the generally accepted MIC
(<0.5 mg/L) for moulds causing infections. These different
target concentrations are possibly explained by dissimilar in-
trapatient variability in the various studies.
Voriconazole TDM should optimally be performed early in
the course of treatment, as soon as a steady state is
reached. To provide a clinically more meaningful analysis of
our data, we analysed separately initial voriconazole concen-
trations determined within 7 days and within 10 days from
the beginning of treatment. Results were similar in all cases,
but failed to reach signiﬁcance in the former analysis (7 days),
owing to the small sample size. Optimal timing for voricona-
zole TDM has not been established, and should be deter-
mined in a prospective manner.
Our data conﬁrm previous reports of associations
between reversible toxicity and higher voriconazole concen-
trations [12,18–20]. Establishment of a threshold for vorico-
nazole safety is difﬁcult, as there is no statistical association
between hepatotoxicity and any particular voriconazole con-
centration [12,20]. Neurotoxicity has been associated with
concentrations >5.5 mg/L [12]. However, clinically signiﬁcant
adverse events have been reported in patients with lower
voriconazole concentrations [19].
From the current data, no clear target concentration or
therapeutic range can be deduced. As outcome is deter-
mined early in the course of IFI [2], it is not surprising that
early low concentrations are consistently associated with
treatment failure and mortality. Given, however, the wide
variability in voriconazole concentrations [12,18,21], it can
also be argued that an adequately sustained concentration of
voriconazole, rather than a target concentration, ensures
treatment success. In addition, for the asymptomatic patient
with a high trough voriconazole concentration detected in
serum, the existing evidence does not justify pre-emptive
dose modiﬁcation towards lower concentrations. In addition,
voriconazole TDM can potentially identify the rare cases
with persistently low concentrations despite intense dose
modiﬁcations that should probably result in alternative
antifungal therapy (if potentially modiﬁable factors have been
excluded).
There are several limitations to this single-centre retro-
spective study of a small heterogeneous cohort with different
IFI types and underlying medical conditions. However, our
patient cohort reﬂects a typical at-risk group [22] with high
rates of post-mortem-conﬁrmed fungus-related mortality. In
the absence of any hospital-wide policy for voriconazole
TDM, monitoring was performed only for selected patients,
on the basis of clinicians’ concerns, and a selection bias is
thus inevitable. However, as only trough concentrations at
steady state were included in our study, a clinically meaning-
ful concentration was documented. The strength of some of
the associations should be interpreted with caution, owing
to our small sample size. Similarly, separate analyses for
mould or yeast infections were not possible, and this may
have concealed the different target levels for the various
fungi. The linearity of results above the upper limit of the
calibration range (5 mg/L) cannot be guaranteed, and a possi-
ble target concentration associated with adverse events may
thus have been obscured. Finally, unrecognized confounders
may have inﬂuenced voriconazole concentrations, e.g. dosing
in relation to food, co-medications, or genetic polymorphism
of the cytochrome enzyme CYP2C19, which can account for
a variability of approximately 30% in voriconazole plasma lev-
els [10,23]. However, genotyping is not routinely available,
and dose adjustments based on results of genotypic tests
have not been proposed as yet for voriconazole [6].
In conclusion, this study supports the association between
voriconazole concentrations and treatment outcome in IFI,
such that TDM should be considered for all patients as soon
as steady state is reached. For patients with trough concen-
trations <0.35 mg/L, dose adjustments should be considered
to achieve and sustain high voriconazole concentrations (aim-
ing for a median voriconazole trough concentration of
>2.2 mg/L). Given the high intrapatient variability and the
lack of an upper cut-off level associated with adverse events,
dose modiﬁcation in asymptomatic patients with high con-
centrations should not be considered. Finally, further studies
are warranted, as a therapeutic range for voriconazole
remains elusive.
Transparency Declaration
No speciﬁc funding has been received for this work. S. Miya-
kis and S. J. van Hal received Pﬁzer sponsorships to attend
international conferences. D. Marriott has been on the advi-
sory board for Pﬁzer, Schering-Plough, and Merck, and has
been on the speakers’ bureau for Pﬁzer and Merck. J. Ray
has no conﬂicts of interest to declare.
932 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 927–933
References
1. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of
voriconazole (UK-109,496), a new triazole antifungal agent, against
emerging and less-common mold pathogens. Antimicrob Agents Chemo-
ther 1997; 41: 841–843.
2. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus
amphotericin B for primary therapy of invasive aspergillosis. N Engl J
Med 2002; 347: 408–415.
3. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of
voriconazole pharmacodynamics using time-kill methodology. Antimic-
rob Agents Chemother 2000; 44: 1917–1920.
4. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics
and pharmacodynamics of a new triazole, voriconazole, in a murine
candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165–3169.
5. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect
of food on the pharmacokinetics of multiple-dose oral voriconazole.
Br J Clin Pharmacol 2003; 56 (suppl 1): 17–23.
6. Maschmeyer G, Haas A. Voriconazole: a broad spectrum triazole for
the treatment of serious and invasive fungal infections. Future Micro-
biol 2006; 1: 365–385.
7. Scott LJ, Simpson D. Voriconazole : a review of its use in the man-
agement of invasive fungal infections. Drugs 2007; 67: 269–298.
8. Denning DW, Ribaud P, Milpied N et al. Efﬁcacy and safety of vorico-
nazole in the treatment of acute invasive aspergillosis. Clin Infect Dis
2002; 34: 563–571.
9. Triﬁlio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels
may be necessary to avoid subtherapeutic levels in hematopoietic
stem cell transplant recipients. Cancer 2007; 109: 1532–1535.
10. US Food and Drug Administration. Brieﬁng document for voriconaz-
ole. Available at: http://www.fda.gov/ohrms/dockets/ac/01/brieﬁng/
3792b2.htm (last accessed 15 July 2008).
11. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug
monitoring. Antimicrob Agents Chemother 2006; 50: 1570–1572.
12. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Vorico-
nazole therapeutic drug monitoring in patients with invasive mycoses
improves efﬁcacy and safety outcomes. Clin Infect Dis 2008; 46: 201–
211.
13. Ascioglu S, Rex JH, de Pauw B et al. Deﬁning opportunistic invasive
fungal infections in immunocompromised patients with cancer and
hematopoietic stem cell transplants: an international consensus. Clin
Infect Dis 2002; 34: 7–14.
14. den Hollander JG, van Arkel C, Rijnders BJ, Lugtenburg PJ, de Marie
S, Levin MD. Incidence of voriconazole hepatotoxicity during intrave-
nous and oral treatment for invasive fungal infections. J Antimicrob
Chemother 2006; 57: 1248–1250.
15. National Cancer Institute. Adverse Event Reporting Requirements:
National Cancer Institute online guidelines 2006. Available at: http://
ctep.cancer.gov/reporting/newadverse_2006.pdf (last accessed 15 July
2008).
16. Pfaller MA, Diekema DJ, Rex JH et al. Correlation of MIC with out-
come for Candida species tested against voriconazole: analysis and
proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819–
826.
17. Triﬁlio S, Singhal S, Williams S et al. Breakthrough fungal infections
after allogeneic hematopoietic stem cell transplantation in patients on
prophylactic voriconazole. Blood 2006; 108: Abstract 2849.
18. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW.
Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241–1244.
19. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse
events to voriconazole: evidence for therapeutic drug monitoring.
Swiss Med Wkly 2006; 136: 739–742.
20. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investiga-
tion of the potential relationships between plasma voriconazole con-
centrations and visual adverse events or liver function test
abnormalities. J Clin Pharmacol 2006; 46: 235–243.
21. Triﬁlio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug
monitoring in allogeneic hematopoietic stem cell transplant recipients.
Bone Marrow Transplant 2005; 35: 509–513.
22. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-
common, emerging, or refractory fungal infections. Clin Infect Dis
2003; 36: 1122–1131.
23. Hyland R, Jones BC, Smith DA. Identiﬁcation of the cytochrome P450
enzymes involved in the N-oxidation of voriconazole. Drug Metab Dis-
pos 2003; 31: 540–547.
CMI Miyakis et al. Voriconazole therapeutic drug monitoring 933
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 927–933
